The LACTEL 50:50 DL-PLG (B6013-2) Biomedical Acid-Terminated PLGA grade is a random poly(DL-lactide-co-glycolide) supplied as an amorphous, free-flowing solid for implantable and drug delivery applications. The designation DL-PLG identifies poly(DL-lactide-co-glycolide) with racemic DL-lactide stereochemistry, while the 50:50 target molar ratio denotes approximately equal lactide and glycolide repeat units in the copolymer backbone. Within the LACTEL nomenclature, the B6013-2 suffix corresponds to a manufacturer-defined molecular-weight range in the acid-terminated 50:50 series. Acid termination provides a terminal carboxylic acid group on each polymer chain, giving the product a measurable acid number that is absent or negligible in ester-terminated grades. Routine release documentation includes inherent viscosity measured in chloroform at 25 °C using USP <911> capillary viscometry or ISO <1628-1>, molecular weight averages and dispersity by gel permeation chromatography, residual lactide and glycolide monomers by gas chromatography, residual solvents by headspace gas chromatography aligned with USP <467>, and tin content by ICP-MS where applicable. The exact acceptance limits vary by lot; the certificate of analysis for each batch is the controlling specification document.

How Does Terminal Carboxylic Acid Functionality Change Hydrolytic Degradation Kinetics?

The terminal carboxylic acid groups in B6013-2 act as proton-donating moieties that lower local pH within the polymer matrix as water ingresses, promoting autocatalytic bulk hydrolysis. In contrast, ester-terminated PLGA of equivalent copolymer ratio and intrinsic viscosity does not present the same density of free acid termini at the initial degradation stage. For a linear acid-terminated chain bearing one terminal carboxyl per molecule, the theoretical acid number is approximately 56,100 divided by Mn, expressed in mg KOH/g; lower-molecular-weight lots therefore exhibit higher carboxyl content. Hydrolysis proceeds by cleavage of ester linkages, with molecular weight reduction preceding mass loss, as observed in phosphate-buffered saline at 37 °C and pH 7.4. The amorphous 50:50 copolymer degrades faster than lactide-rich alternatives because the glycolide units increase backbone hydrophilicity and reduce steric hindrance around the ester bonds. Mass loss typically occurs after the number-average molecular weight falls below a threshold of roughly 5,000–10,000 g/mol, at which soluble oligomers diffuse from the bulk. The specific geometry, porosity, and storage history of the device influence these values; published data for this specific configuration is limited, but the autocatalytic trend is well documented for acid-terminated PLGA systems.

Storage and handling requirements are determined by the hydrolytic sensitivity of the acid-terminated ester backbone. Sealed containers should be stored at −20 °C or lower, with desiccant or inert gas headspace, and allowed to equilibrate to ambient temperature before opening to prevent condensation. Pre-drying under vacuum at or below 30 °C for 24–72 h is commonly specified for solvent-based processing because free water accelerates ester hydrolysis and can shift the molecular-weight distribution. Residual moisture after drying should be verified by Karl Fischer titration according to USP <921>. Storage above the glass-transition temperature can lead to particle fusion or blocking of the powder, so ambient equilibration should be limited. For aseptic processing, filter-sterilized solutions through 0.2 µm PTFE or PVDF membranes are used before solvent extraction or spray drying.

Microsphere, Film, and Fibre Fabrication Routes

B6013-2 is processed by solvent-based routes typical of amorphous 50:50 PLGA. For microsphere manufacturing, polymer is dissolved in dichloromethane at concentrations from 5 to 20 % w/v, and the organic phase is dispersed in an aqueous continuous phase containing poly(vinyl alcohol) or similar stabilizer. A rotor-stator homogenizer operating at 7,000–24,000 rpm or a membrane emulsification unit controls droplet size; solvent extraction into excess water or solvent evaporation under reduced pressure then hardens the particles. Drug loading is achieved by single emulsion for hydrophobic actives or water-in-oil-in-water double emulsion for hydrophilic actives. In film casting, solutions in chloroform or dichloromethane are cast on release liners and dried under controlled airflow, with residual solvent monitored by headspace GC per USP <467>. Electrospinning uses solutions in hexafluoroisopropanol, chloroform, or mixed dichloromethane–dimethylformamide at feed rates of 0.5–2.0 mL/h and potentials of 10–25 kV, producing fibrous scaffolds with fibre diameter influenced by solution viscosity and conductivity.

Thermal processing is possible but requires strict moisture control. Laboratory twin-screw extruders with L/D ratios of 40:1 and temperature zones below the degradation onset are used for compounding; barrel temperatures are commonly kept below 120 °C for short residence times. Acid-terminated PLGA can be more hydrolytically sensitive than ester-terminated material at elevated temperatures and should not be processed without nitrogen purging and pre-drying to 500 ppm moisture or lower. Injection molding clamp force and cavity pressure are application-specific and require validation because the amorphous 50:50 copolymer lacks the crystalline reinforcement of PLLA.

The primary difference between B6013-2 and ester-terminated 50:50 DL-PLG is the terminal chemistry. Ester-terminated polymer chains carry an alkyl ester end group, which reduces the initial carboxylic acid density, lowers the measured acid number, and delays the onset of autocatalytic bulk hydrolysis relative to acid-terminated polymer of similar Mn and architecture. This difference is exploited when carboxyl-functionalized polymer is needed for surface conjugation or for faster erosion in short-duration implants. Compared with 75:25 or 85:15 DL-PLG, the 50:50 copolymer has a lower glass-transition temperature and faster degradation due to the higher glycolide content. Compared with PLLA homopolymer, B6013-2 is amorphous and degrades over a shorter period, whereas PLLA exhibits semicrystalline regions that restrict water uptake and slow mass loss. Exact degradation windows depend on implant size, porosity, sterilization method, and anatomical site; certification of the final device requires ISO <10993-1> biological evaluation, including ISO <10993-5> cytotoxicity and ISO <10993-6> local tissue effects as applicable.

When B6013-2 Replaces Ester-Terminated 50:50 PLGA for Carbodiimide-Mediated Conjugation

The terminal carboxyl groups of B6013-2 enable activation with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide in anhydrous aprotic solvents such as dichloromethane or dimethylformamide. The resulting active ester intermediates couple to primary amine-containing ligands, peptides, or drugs. Ester-terminated 50:50 PLGA cannot undergo the same degree of carbodiimide-mediated conjugation without prior chain scission or end-group transformation. Conjugation efficiency is influenced by acid number, with higher carboxyl density in low-Mn lots providing more reactive sites per gram. However, the same acid terminus accelerates hydrolysis, which can reduce the shelf life of formulated intermediates in humid storage. The table below summarises key differences relevant to process selection.

Gel permeation chromatography is calibrated with polystyrene or polymethyl methacrylate standards, so molecular weight averages are relative rather than absolute; light-scattering detection can provide absolute Mn and Mw. For B6013-2, batch-to-batch variation in residual monomer may influence toxicological assessment, and residual lactide and glycolide should be controlled below the limits established in the device risk assessment. Solubility at ambient temperature is generally high in dichloromethane, chloroform, ethyl acetate, tetrahydrofuran, and acetone; the polymer is insoluble in water, ethanol, and aliphatic hydrocarbons. Acid-terminated grades may show slight solubility differences in mixed solvents compared with ester-terminated grades because terminal carboxyl groups can interact with basic solvents. Filtration of polymer solutions should use low-binding filters because the terminal acid can bind to certain membrane materials; PTFE or PVDF are used for critical filtration steps.

Production-scale handling of B6013-2 requires inert-gas blanketing during solvent storage and closed transfer to avoid atmospheric moisture. Glass or stainless-steel vessels are preferred; contact with strong bases, primary amines in solution, or concentrated acids can accelerate ester hydrolysis. For drug delivery formulations, in-use stability is monitored by GPC and viscosity, with acceptance limits tied to device performance. Terminal sterilization by gamma irradiation or ethylene oxide can reduce molecular weight and alter release kinetics; aseptic filtration into final containers is used where terminal sterilization is not validated. Manufacturers using this product in finished implantable devices should verify polymer identity by Fourier-transform infrared spectroscopy or nuclear magnetic resonance, residual solvents by USP <467>, and biocompatibility under the applicable ISO <10993> series for the final device.

Accelerated degradation screening may be performed in phosphate-buffered saline at 37 °C and pH 7.4, with sampling for molecular weight, mass loss, water uptake, and pH of the medium. For comparison between grades, specimen geometry should be normalised to surface area-to-volume ratio because acid-terminated 50:50 PLGA degrades by bulk erosion and thick implants can display surface-to-centre pH gradients. The lower pH in the core of thick specimens can further accelerate hydrolysis and generate heterogeneous degradation. Published data for this specific configuration is limited; therefore laboratory qualification under ISO <15814> or equivalent standards for absorbable implants is necessary for design control.